Gabapentin's Effect on Agitation in Severely and Persistently Mentally III Patients

Abstract

Spanish

French

OBJECTIVE:

To study the effects of adjunctive gabapentin on agitation in severely and persistently mentally ill (SPMI) inpatients.

METHOD:

Eleven chronic SPMI inpatients on stable psychotropic medication regimens were evaluated before and after the initiation of adjunctive gabapentin for six months. The following psychometric tests were used: Brief Psychiatric Rating Scale (BPRS), Corrigan Agitated Behavior Scale (CABS), and Clinical Global Impression (CGI)–Severity. Data collection was accomplished via retrospective chart review. An internal reliability check indicated that a chart review BPRS is significantly predictive of one performed face-to-face.

RESULTS:

Statistically significant reductions were found at six months for each assessment instrument (p > 0.05, two-tailed). BPRS scores were reduced from 40.6 to 33.2, CABS from 34.4 to 25.0, and CGI—Severity from 5.9 to 5.3. The bulk of the BPRS reduction was accounted for by several subscores exclusive of those assessing affective/anxious symptomatology. Adverse effects were minimal. Two patients were discharged 12 and 17 months after implementation of gabapentin.

CONCLUSIONS:

Adjunctive gabapentin appears to be associated with a reduction in agitation in chronically hospitalized SPMI patients. Controlled, prospective trials are needed before any definitive conclusion can be drawn regarding the role of gabapentin in the treatment of this group of patients.

Keywords

adjunctive gabapentin agitation reduction mental illness

Get full access to this article

View all access options for this article.

References

Bruni

Saunders

Anhut

. Efficacy and safety of gabapentin (neurontin): A multicenter, placebo-controlled, double-blind study. Neurology 1991; 41 (suppl 1):330–1.

U.S. Gabapentin Study Group No. 5a. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel group study. Neurology 1993; 43: 2292–8.

Ghaemi

Katzow

Desai

Goodwin

. Gabapentin treatment of mood disorders: A preliminary study. J Clin Psychiatry 1998; 59: 426–9.

McElroy

Soutullo

Keck

Kmetz

. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9: 99–103.

Schaffer

. Gabapentin in the treatment of bipolar disorder (letter). Am J Psychiatry 1997; 154: 291–2.

Young

Robb

Patelis-Siotis

MacDonald

Joffe

. Acute treatment of depression with gabapentin. Biol Psychiatry 1997; 42: 851–3.

Pande

Davidson

JRT

Jefferson

Janny

Katzelnick

Weisler

. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–8.

Lettermen

Markowitz

. Gabapentin: A review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacother 1999; 19: 565–72.

Ryback

Brodsky

Manasifi

. Gabapentin in bipolar disorder (letter). Neuropsychiatry Clin Neurosci 1997; 9: 301.

10.

Ryback

. Gabapentin in behavioral dyscontrol. Am J Psychiatry (letter). 1995;152: 1399.

11.

Regan

Gordon

. Gabapentin for behavioral agitation in Alzheimer's disease (letter). J Clin Psychopharmacol 1997; 17: 59–60.

12.

Low

Jr. Brandis

. Gabapentin for management of agitation (letter). J Clin Psychopharmacol 1999; 19: 482–3.

13.

Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington, DC: American Psychiatric Association, 1987.

14.

Corrigan

. Development of a scale for assessment of agitation following traumatic brain injury. J Clin Exp Neuropsychol 1989; 11: 261–77.

15.

Corrigan

Bogner

. Factor structure of the agitated behavior scale. J Clin Exp Neuropsychol 1994; 16: 386–92.

16.

Guy

. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Dept. of Health, Education, and Welfare publication (ADM) 76–338. National Institute of Mental Health; 1976: 218–22.

17.

Overall

Gorham

. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812.

18.

Post

. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999–1010.

19.

Wright

Birkett

David

Meehan

Ferchland

Alaka

. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51.